Christopher J. Melani, MD, discusses updated data from the phase 1b/2 ViPOR trial of the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, in patients with diffuse large B-cell lymphoma.
Christopher J. Melani, MD, assistant research physician in the Lymphoid Malignancies Branch at the Center for Cancer Research, National Cancer Institute, discusses updated data from the phase 1b/2 ViPOR trial (NCT03223610) of the combination of venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone, obinutuzumab (Gazyva), and lenalidomide (Revlimid), in patients with diffuse large B-cell lymphoma (DLBCL).
According to Melani, the combination, which is given in short, non-continuous cycles, showed promising safety and efficacy results and was well-tolerated across all ages. A total of 38% of patients achieved complete remission (CR), and these rates were even higher in certain subtypes.
While further research is needed, the ViPOR study represents a potentially transformative approach for patients with DLBCL.
Transcription:
0:10 | I presented data for the relapsed/refractory cohort of the ViPOR study. ViPOR is a novel combination targeted therapy regimen building on some of the synergy that we've seen in preclinical studies of DLBCL, combining several agents that target B-cell receptor signaling, such as ibrutinib, prednisone, as well as lenalidomide, in addition to venetoclax, which targets BCL2 and apoptosis, and obinutuzumab which facilitates innate immunity through CD20. It really is a novel concept because it's modeled after cytotoxic chemotherapy, where all of the targeted agents are given in non continuous cycles, so 2 weeks of study drug, 1 week break for a fixed duration. So only 6 cycles or 18 weeks without any maintenance therapy.
0:53 | What was impressive regarding this regimen is 1: it was extremely safe and tolerable for patients of all ages, even upwards into their 80s, compared [with] other types of regimens such as cytotoxic chemotherapy, and it was very effective.
1:10 | Overall the rate of complete remission was 38% in patients with relapsed/refractory large cell [lymphoma], with a median line of therapy of 3. In some subtypes, such as the ABC or non GCB subtype of diffuse large B-cell lymphoma, as well as high grade B-cell lymphoma double-hit BCL2, the CR rates were in the 62% and 53% range, respectively. Despite the time-limited therapy of only 6 cycles, these remissions were very durable. Overall, our 2-year progression-free survival was 34%. In double-hit, it was 47%, and in high-grade B-cell lymphoma, it was 38% and a median follow-up of 40 months. These were very deep and durable remissions, despite a very fixed limited therapy.
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
Saeed Discusses Long-Term Outcomes and Real-World Data for Tafasitamab/ Lenalidomide in R/R DLBCL
August 15th 2024During an in-person Community Case Forum event, Hayder Saeed, MD, discussed the RE-MIND2 matched cohort data and real-world data on the combination of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.
Read More
Takeaways on Tolerability Challenges With Loncastuximab in DLBCL
July 30th 2024During a Case-Based Roundtable® event, Amitkumar Mehta, MD, discussed the study design of the LOTIS-2 trial and adverse events related to loncastuximab tesirine in diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab/Chemo Leads to Survival Benefit in Transplant-Ineligible R/R DLBCL
July 3rd 2024A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.
Read More